Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.68 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.66 |
| ▸ | CDK9 | P50750 | 4/20 | 0.66 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.59 |
| ▸ | CCND1 | P24385 | 1/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.59 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349877 | 1.00 | GSK3B (0.68) | GSK3BCCNT1CDK9CAMK2DCDK2 | |
| SCHEMBL7195024 | 0.92 | CCNT1 (0.76) | GSK3BCCNT1CDK9CDK2CCNE2 | |
| SCHEMBL7815802 | 0.82 | CCNT1 (0.66) | GSK3BCCNT1CDK9CDK2CCNE2 | |
| SCHEMBL9572022 | 0.82 | GSK3B (0.64) | GSK3BCCNT1CDK9CDK2CCNE2 | |
| SCHEMBL7508106 | 0.82 | CCNT1 (0.61) | GSK3BCCNT1CDK9CDK2CCNE2 | |
| SCHEMBL29383914 | 0.82 | CCNT1 (0.61) | GSK3BCCNT1CDK9CDK2CCNE2 | |
| SCHEMBL29419482 | 0.82 | CCNT1 (0.61) | GSK3BCCNT1CDK9CDK2CCNE2 | |
| SCHEMBL6581547 | 0.82 | CCNT1 (0.61) | GSK3BCCNT1CDK9CDK2CCNE2 | |
| SCHEMBL6950992 | 0.81 | GSK3B (0.94) | GSK3BCDK2CCNE2CDK4CCND1 | |
| SCHEMBL29386790 | 0.81 | CCNT1 (0.60) | GSK3BCCNT1CDK9CDK2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087949-A1 | Indolylpyrrole derivatives and cell death inhibitors | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2003-05-08 | — | — | US | disclosed |
| EP-1275646-A1 | INDOLYLPYRROLE DERIVATIVES AND CELL DEATH INHIBITORS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087949-A1 | Indolylpyrrole derivatives and cell death inhibitors | AIFM1, BAX, CASP3 | GSK3B 181/4885CCNT1 683/4885CDK9 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.